Abstract
A number of recent studies revealed that successful treatment of the patients with MDR/XDR- TB was not achieved due to high resistant rates to many second-line drugs such as kanamycin and prothionamide including poor adherence of the lengthy treatment. Many new drugs and compounds such as benzothiazinones, meropenem, PA-824, isoflavonoids, rhein, PNU-100480, TMC207, SQ109, OPC-67683, AZD5847, and linezolid are currently in development pipeline. According to very few patents in new compounds and drugs against MDR/XDRMycobacterium tuberculosis bacilli have been currently introduced, so inventors must be encouraged to contribute to this area worldwide.
Keywords: Multidrug, extensively-drug, resistant, tuberculosis, compounds, novel, patents
Recent Patents on Anti-Infective Drug Discovery
Title:Novel Compounds and Drugs and Recent Patents in Treating Multidrug- Resistant and Extensively Drug-Resistant Tuberculosis
Volume: 7 Issue: 2
Author(s): Attapon Cheepsattayakorn and Ruangrong Cheepsattayakorn
Affiliation:
Keywords: Multidrug, extensively-drug, resistant, tuberculosis, compounds, novel, patents
Abstract: A number of recent studies revealed that successful treatment of the patients with MDR/XDR- TB was not achieved due to high resistant rates to many second-line drugs such as kanamycin and prothionamide including poor adherence of the lengthy treatment. Many new drugs and compounds such as benzothiazinones, meropenem, PA-824, isoflavonoids, rhein, PNU-100480, TMC207, SQ109, OPC-67683, AZD5847, and linezolid are currently in development pipeline. According to very few patents in new compounds and drugs against MDR/XDRMycobacterium tuberculosis bacilli have been currently introduced, so inventors must be encouraged to contribute to this area worldwide.
Export Options
About this article
Cite this article as:
Cheepsattayakorn Attapon and Cheepsattayakorn Ruangrong, Novel Compounds and Drugs and Recent Patents in Treating Multidrug- Resistant and Extensively Drug-Resistant Tuberculosis, Recent Patents on Anti-Infective Drug Discovery 2012; 7 (2) . https://dx.doi.org/10.2174/157489112801619683
DOI https://dx.doi.org/10.2174/157489112801619683 |
Print ISSN 1574-891X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4071 |
Related Articles
-
Modern Drug Discovery Technologies: Opportunities and Challenges in Lead Discovery
Combinatorial Chemistry & High Throughput Screening Inhibitors of the Purine Salvage Pathway: A Valuable Approach for Antiprotozoal Chemotherapy?
Current Medicinal Chemistry Do You See What I See: Recognition of Protozoan Parasites by Toll-Like Receptors
Current Immunology Reviews (Discontinued) Identification and Characterization of a Novel Oligomeric Decaprenyl Diphosphate Synthase
Protein & Peptide Letters Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy
Current Diabetes Reviews Design, Synthesis and Antitubercular Evaluation of New Benzimidazole Scaffolds
Anti-Infective Agents Biology of gama delta T Cells in Tuberculosis and Malaria
Current Molecular Medicine Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Chemical Mechanisms, Structure-Activity Relationships and Relationship to Clinical Drug-Drug Interactions and Idiosyncratic Adverse Drug Reactions
Current Drug Metabolism Anti-Mycobacterial Peroxides: A New Class of Agents for Development Against Tuberculosis
Medicinal Chemistry Synthesis, Antitrypanosomal and Antimycobacterial Activities of Coumarin N-acylhydrazonic Derivatives
Medicinal Chemistry Multifunctional Enzymes as Targets for the Treatment of Tuberculosis: Paving the Way for New Anti-TB Drugs
Current Medicinal Chemistry TNF as a Target of Inflammation in Rheumatoid Arthritis
Endocrine, Metabolic & Immune Disorders - Drug Targets MIF and CD74 - Suitability as Clinical Biomarkers
Mini-Reviews in Medicinal Chemistry Structure-based Virtual Screening to Get New Scaffold Inhibitors of the Ser/Thr Protein Kinase PknB from Mycobacterium tuberculosis
Letters in Drug Design & Discovery Eradicating Bacterial Biofilms with Natural Products and their Inspired Analogues that Operate Through Unique Mechanisms
Current Topics in Medicinal Chemistry Exploiting Innate γδ T Lymphocytes for Tumor Immunotherapy
Recent Patents on Biomarkers A Systematic Review of Lifestyle Modification and Glucose Intolerance in the Prevention of Type 2 Diabetes
Current Diabetes Reviews Inter-Species/Host-Parasite Protein Interaction Predictions Reviewed
Current Bioinformatics Improvements in Algorithms for Phenotype Inference: The NAT2 Example
Current Drug Metabolism Quinolones in the Search for New Anticancer Agents
Current Pharmaceutical Design